Which has better earnings and valuation, LW or MED?

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lamb Weston $6.45B 0.89 $357.20M $2.14 19.46 Medifast $385.79M 0.36 -$18.67M -$1.83 N/A

Is LW or MED more profitable?

Lamb Weston has a net margin of 4.61% compared to Medifast's net margin of -5.78%. Lamb Weston's return on equity of 23.77% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Lamb Weston 4.61% 23.77% 5.76% Medifast -5.78% -4.80% -3.83%

Does the media prefer LW or MED?

In the previous week, Medifast had 2 more articles in the media than Lamb Weston. MarketBeat recorded 13 mentions for Medifast and 11 mentions for Lamb Weston. Lamb Weston's average media sentiment score of 0.80 beat Medifast's score of 0.37 indicating that Lamb Weston is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lamb Weston 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medifast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, MED or NOMD?

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medifast $385.79M 0.36 -$18.67M -$1.83 N/A Nomad Foods $3.43B 0.41 $154.66M $1.03 9.77

Is MED or NOMD more profitable?

Nomad Foods has a net margin of 4.43% compared to Medifast's net margin of -5.78%. Nomad Foods' return on equity of 9.05% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Medifast -5.78% -4.80% -3.83% Nomad Foods 4.43% 9.05% 3.61%

Does the media refer more to MED or NOMD?

In the previous week, Medifast had 11 more articles in the media than Nomad Foods. MarketBeat recorded 13 mentions for Medifast and 2 mentions for Nomad Foods. Nomad Foods' average media sentiment score of 1.13 beat Medifast's score of 0.37 indicating that Nomad Foods is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nomad Foods 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MED or NATR?

In the previous week, Medifast had 11 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 13 mentions for Medifast and 2 mentions for Nature's Sunshine Products. Nature's Sunshine Products' average media sentiment score of 1.51 beat Medifast's score of 0.37 indicating that Nature's Sunshine Products is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nature's Sunshine Products 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer MED or USNA?

Medifast currently has a consensus price target of $12.00, suggesting a potential downside of 3.05%. Given Medifast's higher possible upside, analysts plainly believe Medifast is more favorable than USANA Health Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medifast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 USANA Health Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor MED or USNA?

In the previous week, Medifast had 7 more articles in the media than USANA Health Sciences. MarketBeat recorded 13 mentions for Medifast and 6 mentions for USANA Health Sciences. Medifast's average media sentiment score of 0.37 beat USANA Health Sciences' score of 0.29 indicating that Medifast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral USANA Health Sciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NUS or MED?

Medifast has a consensus target price of $12.00, suggesting a potential downside of 3.05%. Given Medifast's higher probable upside, analysts plainly believe Medifast is more favorable than Nu Skin Enterprises. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nu Skin Enterprises 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Medifast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Medifast (MED) Competitors

$12.38 -0.32 (-2.54%)

Closing price 06/2/2026 03:59 PM Eastern

Extended Trading

$12.49 +0.11 (+0.91%)

As of 09:02 AM Eastern

Compare

MED vs. LW, NOMD, NATR, USNA, and NUS

Should you buy Medifast stock or one of its competitors? MarketBeat compares Medifast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medifast include Lamb Weston (LW), Nomad Foods (NOMD), Nature's Sunshine Products (NATR), USANA Health Sciences (USNA), and Nu Skin Enterprises (NUS).

How does Medifast compare to Lamb Weston?

Lamb Weston (NYSE:LW) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Lamb Weston has a net margin of 4.61% compared to Medifast's net margin of -5.78%. Lamb Weston's return on equity of 23.77% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lamb Weston	4.61%	23.77%	5.76%
Medifast	-5.78%	-4.80%	-3.83%

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lamb Weston	$6.45B	0.89	$357.20M	$2.14	19.46
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A

Lamb Weston has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Medifast has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

In the previous week, Medifast had 2 more articles in the media than Lamb Weston. MarketBeat recorded 13 mentions for Medifast and 11 mentions for Lamb Weston. Lamb Weston's average media sentiment score of 0.80 beat Medifast's score of 0.37 indicating that Lamb Weston is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lamb Weston	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medifast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.6% of Lamb Weston shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 0.3% of Lamb Weston shares are owned by company insiders. Comparatively, 3.7% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lamb Weston currently has a consensus target price of $47.82, suggesting a potential upside of 14.82%. Medifast has a consensus target price of $12.00, suggesting a potential downside of 3.05%. Given Lamb Weston's stronger consensus rating and higher possible upside, analysts clearly believe Lamb Weston is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lamb Weston	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Lamb Weston beats Medifast on 12 of the 16 factors compared between the two stocks.

How does Medifast compare to Nomad Foods?

Medifast (NYSE:MED) and Nomad Foods (NYSE:NOMD) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A
Nomad Foods	$3.43B	0.41	$154.66M	$1.03	9.77

Nomad Foods has a net margin of 4.43% compared to Medifast's net margin of -5.78%. Nomad Foods' return on equity of 9.05% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Nomad Foods	4.43%	9.05%	3.61%

95.5% of Medifast shares are owned by institutional investors. Comparatively, 75.3% of Nomad Foods shares are owned by institutional investors. 3.7% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Medifast presently has a consensus price target of $12.00, suggesting a potential downside of 3.05%. Nomad Foods has a consensus price target of $12.50, suggesting a potential upside of 24.19%. Given Nomad Foods' stronger consensus rating and higher probable upside, analysts clearly believe Nomad Foods is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nomad Foods	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Medifast has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Nomad Foods has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Medifast had 11 more articles in the media than Nomad Foods. MarketBeat recorded 13 mentions for Medifast and 2 mentions for Nomad Foods. Nomad Foods' average media sentiment score of 1.13 beat Medifast's score of 0.37 indicating that Nomad Foods is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nomad Foods	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nomad Foods beats Medifast on 13 of the 16 factors compared between the two stocks.

How does Medifast compare to Nature's Sunshine Products?

Medifast (NYSE:MED) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap personal products companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

In the previous week, Medifast had 11 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 13 mentions for Medifast and 2 mentions for Nature's Sunshine Products. Nature's Sunshine Products' average media sentiment score of 1.51 beat Medifast's score of 0.37 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nature's Sunshine Products	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Medifast presently has a consensus target price of $12.00, suggesting a potential downside of 3.05%. Nature's Sunshine Products has a consensus target price of $35.00, suggesting a potential upside of 67.95%. Given Nature's Sunshine Products' stronger consensus rating and higher possible upside, analysts clearly believe Nature's Sunshine Products is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nature's Sunshine Products	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Nature's Sunshine Products has a net margin of 4.06% compared to Medifast's net margin of -5.78%. Nature's Sunshine Products' return on equity of 14.67% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Nature's Sunshine Products	4.06%	14.67%	9.27%

95.5% of Medifast shares are held by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are held by institutional investors. 3.7% of Medifast shares are held by insiders. Comparatively, 3.1% of Nature's Sunshine Products shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Medifast has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Nature's Sunshine Products has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Nature's Sunshine Products has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A
Nature's Sunshine Products	$480.14M	0.76	$19.52M	$1.10	18.95

Summary

Nature's Sunshine Products beats Medifast on 13 of the 16 factors compared between the two stocks.

How does Medifast compare to USANA Health Sciences?

Medifast (NYSE:MED) and USANA Health Sciences (NYSE:USNA) are both small-cap personal products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

USANA Health Sciences has a net margin of 0.96% compared to Medifast's net margin of -5.78%. USANA Health Sciences' return on equity of 6.21% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
USANA Health Sciences	0.96%	6.21%	4.50%

Medifast currently has a consensus price target of $12.00, suggesting a potential downside of 3.05%. Given Medifast's higher possible upside, analysts plainly believe Medifast is more favorable than USANA Health Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
USANA Health Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

95.5% of Medifast shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 3.7% of Medifast shares are owned by company insiders. Comparatively, 0.8% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

USANA Health Sciences has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A
USANA Health Sciences	$925.26M	0.36	$10.76M	$0.47	38.49

In the previous week, Medifast had 7 more articles in the media than USANA Health Sciences. MarketBeat recorded 13 mentions for Medifast and 6 mentions for USANA Health Sciences. Medifast's average media sentiment score of 0.37 beat USANA Health Sciences' score of 0.29 indicating that Medifast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
USANA Health Sciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medifast has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, USANA Health Sciences has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Summary

USANA Health Sciences beats Medifast on 9 of the 14 factors compared between the two stocks.

How does Medifast compare to Nu Skin Enterprises?

Nu Skin Enterprises (NYSE:NUS) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Medifast has a consensus target price of $12.00, suggesting a potential downside of 3.05%. Given Medifast's higher probable upside, analysts plainly believe Medifast is more favorable than Nu Skin Enterprises.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nu Skin Enterprises	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Nu Skin Enterprises has a net margin of 3.78% compared to Medifast's net margin of -5.78%. Nu Skin Enterprises' return on equity of 7.47% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nu Skin Enterprises	3.78%	7.47%	4.21%
Medifast	-5.78%	-4.80%	-3.83%

Nu Skin Enterprises has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nu Skin Enterprises, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nu Skin Enterprises	$1.44B	0.19	$160.20M	$1.10	5.10
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A

In the previous week, Medifast had 13 more articles in the media than Nu Skin Enterprises. MarketBeat recorded 13 mentions for Medifast and 0 mentions for Nu Skin Enterprises. Nu Skin Enterprises' average media sentiment score of 0.50 beat Medifast's score of 0.37 indicating that Nu Skin Enterprises is being referred to more favorably in the media.

Company	Overall Sentiment
Nu Skin Enterprises	Positive
Medifast	Neutral

Nu Skin Enterprises has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Medifast has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

82.8% of Nu Skin Enterprises shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 2.8% of Nu Skin Enterprises shares are held by company insiders. Comparatively, 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Nu Skin Enterprises beats Medifast on 10 of the 15 factors compared between the two stocks.

Get Medifast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MED vs. The Competition

Export

Metric	Medifast	FOOD Industry	Staples Sector	NYSE Exchange
Market Cap	$141.21M	$7.40B	$15.82B	$23.18B
Dividend Yield	N/A	4.34%	3.53%	4.09%
P/E Ratio	-6.76	15.64	25.94	31.31
Price / Sales	0.36	1.19	46.94	24.47
Price / Cash	30.60	9.62	16.95	24.80
Price / Book	0.68	2.64	5.63	4.74
Net Income	-$18.67M	$223.87M	$676.04M	$1.07B
7 Day Performance	-2.22%	-1.04%	-0.83%	0.62%
1 Month Performance	13.42%	-3.68%	-2.26%	1.54%
1 Year Performance	-9.19%	-13.89%	-11.84%	26.87%

Medifast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MED Medifast	1.4904 of 5 stars	$12.38 -2.5%	$12.00 -3.1%	-6.9%	$141.21M	$385.79M	N/A	870
LW Lamb Weston	4.9327 of 5 stars	$43.67 +2.0%	$48.00 +9.9%	-24.0%	$6.04B	$6.45B	20.41	10,100
NOMD Nomad Foods	4.978 of 5 stars	$10.27 +1.4%	$12.50 +21.7%	-41.9%	$1.44B	$3.43B	9.97	7,752	Positive News
NATR Nature's Sunshine Products	3.9279 of 5 stars	$21.85 0.0%	$35.00 +60.2%	+48.4%	$384.23M	$480.14M	19.86	850
USNA USANA Health Sciences	2.6495 of 5 stars	$18.79 +1.2%	N/A	-38.0%	$346M	$925.26M	39.97	1,570	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MED) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medifast (MED) Competitors

MED vs. LW, NOMD, NATR, USNA, and NUS

How does Medifast compare to Lamb Weston?

Summary

How does Medifast compare to Nomad Foods?

Summary

How does Medifast compare to Nature's Sunshine Products?

Summary

How does Medifast compare to USANA Health Sciences?

Summary

How does Medifast compare to Nu Skin Enterprises?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medifast (MED) Competitors

MED vs. LW, NOMD, NATR, USNA, and NUS

How does Medifast compare to Lamb Weston?

Is LW or MED more profitable?

Which has better earnings and valuation, LW or MED?

Which has more volatility & risk, LW or MED?

Does the media prefer LW or MED?

Do institutionals and insiders have more ownership in LW or MED?

Do analysts rate LW or MED?

Summary

How does Medifast compare to Nomad Foods?

Which has stronger earnings & valuation, MED or NOMD?

Is MED or NOMD more profitable?

Do institutionals & insiders hold more shares of MED or NOMD?

Do analysts rate MED or NOMD?

Which has more risk and volatility, MED or NOMD?

Does the media refer more to MED or NOMD?

Summary

How does Medifast compare to Nature's Sunshine Products?

Does the media favor MED or NATR?

Do analysts prefer MED or NATR?

Is MED or NATR more profitable?

Do insiders & institutionals hold more shares of MED or NATR?

Which has more volatility & risk, MED or NATR?

Which has stronger earnings and valuation, MED or NATR?

Summary

How does Medifast compare to USANA Health Sciences?

Is MED or USNA more profitable?

Do analysts prefer MED or USNA?

Do insiders and institutionals hold more shares of MED or USNA?

Which has higher valuation and earnings, MED or USNA?

Does the media favor MED or USNA?

Which has more volatility and risk, MED or USNA?

Summary

How does Medifast compare to Nu Skin Enterprises?

Do analysts prefer NUS or MED?

Is NUS or MED more profitable?

Which has stronger valuation & earnings, NUS or MED?

Does the media prefer NUS or MED?

Which has more risk & volatility, NUS or MED?

Do institutionals & insiders believe in NUS or MED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools